

Edited by

Camille Georges Wermuth

David Aldous


Pierre Raboisson

Didier Rognan

THE PRACTICE OF

MEDICINAL

CHEMISTRY



FOURTH EDITION



THE PRACTICE OF
MEDICINAL CHEMISTRY

FOURTH EDITION

The Practice of Medicinal Chemistry

FOURTH EDITION

Edited by

CAMILLE GEORGES WERMUTH, PhD, PHARM D

Founder of Prestwick Chemical, Strasbourg, France

DAVID ALDOUS, BSc, DPhil

Boston Head Lead Generation to Candidate Realisation, Boston, MA, USA

PIERRE RABOISSON, PhD, PHARM D

Janssen Infectious Diseases and Diagnostics BVBA, Beerse, Belgium

DIDIER ROGNAN, PhD, PHARM D

Laboratoire d'Innovation Thérapeutique, CNRS-Université de Strasbourg, Illkirch, France



AMSTERDAM • BOSTON • HEIDELBERG • LONDON
NEW YORK • OXFORD • PARIS • SAN DIEGO
SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO

Academic Press is an imprint of Elsevier



Academic Press is an imprint of Elsevier
125, London Wall, EC2Y 5AS
525 B Street, Suite 1800, San Diego, CA 92101-4495, USA
225 Wyman Street, Waltham, MA 02451, USA
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK

Copyright © 2015 Elsevier Ltd. All rights reserved.

First edition 1996
Reprinted 2001
Second edition 2003
Third edition 2008

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the Publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers may always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

ISBN: 978-0-12-417205-0

For information on all Academic Press publications
visit our website at <http://store.elsevier.com>



Working together
to grow libraries in
developing countries

www.elsevier.com • www.bookaid.org

Contents

List of Contributors	xi	VII. Target Validation	68
Foreword	xiii	VIII. Conclusion	68
Preface to the Fourth Edition	xv	References	68
Preface to the Third Edition	xvii		
Preface to the Second Edition	xix		
Preface to the First Edition	xxi		

I

GENERAL ASPECTS OF MEDICINAL CHEMISTRY

1. Medicinal Chemistry: Definitions and Objectives, Drug Activity Phases, Drug Classification Systems

PETER IMMING

I. Definitions and Objectives	3
II. Drug Activity Phases	7
III. Drug Classification Systems	8
References	12

2. Evaluation of the Biological Activity of Compounds: Techniques and Mechanism of Action Studies

IAIN G. DOUGALL AND JOHN UNITT

I. Introduction	15
II. Drug Discovery Approaches and Screening Cascades	16
III. <i>In Vitro</i> Assays	17
IV. <i>Ex Vivo</i> Assays	38
V. <i>In Vivo</i> Assays	39
Acknowledgements	42
References	42

3. Drug Targets, Target Identification, Validation, and Screening

WALTER M.M. VAN DEN BROECK

I. Introduction	45
II. What is a Drug Target?	46
III. The Purpose of Target Identification	47
IV. Target Options and Treatment Options	51
V. Target Deconvolution and Target Discovery	53
VI. Methods for Target Identification and Validation	54

II

LEAD COMPOUND DISCOVERY STRATEGIES

4. Strategies in the Search for New Lead Compounds or Original Working Hypotheses

CAMILLE G. WERMUTH, BRUNO VILLOUTREIX, SERGE GRISONI,
ANNE OLIVIER AND JEAN-PHILIPPE ROCHER

I. Introduction	73
II. First Strategy: Analog Design	74
III. Second Strategy: Systematic Screening	78
IV. Third Strategy: Exploitation of Biological Information	84
V. Fourth Strategy: Planned Research and Rational Approaches	90
VI. Fifth Strategy: Applying Biophysical Technologies and Computational Methods	93
VII. Conclusion	96
References	96

5. Natural Products as Pharmaceuticals and Sources for Lead Structures

DAVID J. NEWMAN, GORDON M. CRAGG AND DAVID G.I. KINGSTON

I. Introduction	102
II. The Importance of Natural Products in Drug Discovery and Development	102
III. The Design of an Effective Natural-Products-Based Approach to Drug Discovery	106
IV. Examples of Natural Products or Analogues as Drugs	116
V. Future Directions in Natural Products as Drugs and Drug Design Templates	128
VI. Summary	130
References	131

6. *In Silico* Screening: Hit Finding from Database Mining

TIAGO RODRIGUES AND GIBBERT SCHNEIDER

I. Introduction	141
II. <i>In Silico</i> Screening	143
III. <i>De Novo</i> Design	150

IV. Conclusions and Future Directions	154
Glossary	156
References	156

7. Fragment-Based Drug Discovery

VENKATA VELVADAPU, BENNETT T. FARMER AND ALLEN B. REITZ

I. Ligand-Protein Interactions: First Principles	162
II. What is Fragment-Based Drug Discovery?	164
III. Creation and Analysis of FBDD Libraries	166
IV. Fragment Screening Methods	167
V. Other Biochemical and Biophysical Methods	171
VI. Fragment Merging/Linking/Growing	172
VII. Fragment Hit Follow-Up, and Pitfalls to Avoid	174
VIII. Zelboraf [®] , First Approved Drug from FBDD	175
IX. Limitations of FBDD	176
X. Trends for the Future	176
References	177

8. Molecular Variations Based on Isosteric Replacements

PAOLA CIAPETTI AND BRUNO GIETHLEN

I. Introduction	181
II. History: Development of the Isosterism Concept	182
III. Currently Encountered Isosteric and Bioisosteric Modifications	186
IV. Scaffold Hopping	220
V. Analysis of the Modifications Resulting from Isosterism	224
VI. Minor Metalloids-Toxic Isosteres	229
References	233

9. Ring Transformations

CHRISTOPHE MORICE AND CAMILLE G. WERMUTH

I. Introduction	243
II. Analogical Approaches	244
III. Disjunctive Approaches	258
IV. Conjunctive Approaches	260
V. Conclusion	263
References	263

10. Macrocycles: Under-Explored and Poorly Exploited Drug Class Despite the Proven Therapeutic Potential

PIERRE RABOISSON

I. Nature as a Source of Macrocycles	267
II. Identification of Macrocyclic Drugs Using Either Phenotypic Screen or Target-Based Approach	268
III. Macrocycles: The Drugs in the Middle Space	270
IV. Effect of the Macrocyclization on Drug-Like Properties	270
V. Interaction of Macrocycles with their Targets	271
VI. Synthesis of Macrocycles & Library Enrichment	274
VII. Conclusion	274
References	274

III

PRIMARY EXPLORATION OF STRUCTURE-ACTIVITY RELATIONSHIPS

11. Conformational Restriction and Steric Hindrance in Medicinal Chemistry

PETER WIPE, ERIN M. SKODA AND ANDRÉ MANN

I. Introduction	279
II. Case Studies	285
III. Summary and Outlook	297
References	297

12. Application Strategies for the Primary Structure-Activity Relationship Exploration

CAMILLE G. WERMUTH, SERGE GRISONI, BRUNO VILLOUTREIX AND JEAN-PHILIPPE ROCHER

I. Introduction	302
II. Preliminary Considerations	302
III. Hit Optimization Strategies	303
IV. Application Rules	312
References	317

13. Substituent Groups

PATRICK BAZZINI AND CAMILLE G. WERMUTH

I. Introduction	319
II. Methyl Groups	320
III. Effects of Unsaturated Groups	331
IV. Effects of Halogenation	338
V. Effects of Hydroxylation	345
VI. Effects of Thiols and Other Sulfur-Containing Groups	346
VII. Acidic Functions	349
VIII. Basic Groups	351
IX. Attachment of Additional Binding Sites	352
References	354

14. The Role of Functional Groups in Drug-Receptor Interactions

LAURENT SCHAEFFER

I. Introduction	359
II. General Principles	360
III. The Importance of the Electrostatic and Steric Match Between Drug and Receptor	360
IV. The Strengths of Functional Group Contributions to Drug-Receptor Interactions	370
V. Cooperative Binding	376
References	377

15. Compound Properties and their Influence on Drug Quality

HONGMING CHEN, OLA ENGVIST AND THIERRY KOGEJ

I. Introduction	379
II. Compound Drug-Likeness Analysis	380
III. Compound Promiscuity	382
IV. Compound ADMET Properties	384
V. Ligand Binding Efficiency Metrics	386
VI. Conclusions and Future Outlook	390
References	391

16. Pharmacological Space

ANDREW L. HOPKINS

I. What is Pharmacological Space?	395
II. Chemical Space	395
III. Target Space	399
IV. Conclusions	405
Acknowledgments	407
References	407

17. Systems Biology: A New Paradigm for Drug Discovery

HIBA ABI HUSSEIN, ALEXANDRE BORREL, LESLIE REGAD, DELPHINE FLATTERS, ANNE BADEL, COLETTE GENEIX, MICHEL PETTJEAN, ANNE-CLAUDE CAMPROUX AND OLIVIER TABOUREAU

I. Introduction	409
II. Drug-Target Space (off-target)	413
III. Systems Biology Space	415
IV. Phenotype Space	418
V. Examples	418
VI. Conclusion	421
References	421

IV

SUBSTITUENTS AND FUNCTIONS: QUALITATIVE ASPECTS OF STRUCTURE-ACTIVITY RELATIONSHIPS

18. Optical Isomerism in Drugs

CAMILLE G. WERMUTH

I. Introduction	429
II. Experimental Facts and their Interpretation	430
III. Optical Isomerism and Pharmacodynamic Aspects	435
IV. Optical Isomerism and Pharmacokinetic Aspects	437
V. Practical Considerations	439
References	444

19. Multitarget Drugs: Strategies and Challenges for Medicinal Chemists

RICHARD MORPHY AND ZORAN RANKOVIC

I. Introduction	449
II. Strategies for Lead Generation	451
III. Main Areas of Focus in Discovery	453
IV. Optimization of the Activity Profile and Wider Selectivity	465
V. The Physicochemical Challenge	467
VI. Summary	469
References	470

20. Selective Optimization of Side Activities (SOSA) in Drug Discovery

TIM JONCKERS

I. Introduction	473
II. Ritonavir: Rejuvenating a Suboptimal Drug	474
III. Sildenafil, Side Effects are Not Always Bad	477
IV. Nucleotide Prodrugs: Chemical Trojan Horses	478
V. Miltefosine	481
VI. Aztreonam	483
VII. Conclusions	485
References	485

V

SPATIAL ORGANIZATION, RECEPTOR MAPPING AND MOLECULAR MODELING

21. Pharmacophore Identification and Pseudo-Receptor Modeling

GERHARD WOLBER AND WOLFGANG SIPPL

I. Introduction	489
II. Methodology	493
III. Advanced Approaches	497
IV. Application Study: Novel Histamine H ₃ -Receptor Antagonists	501
V. Recent Developments and Outlook	505
VI. Conclusions	507
References	507

22. Protein Crystallography and Drug Discovery

JEAN-MICHEL RONDEAU AND HERMAN SCHREUDER

I. Introduction	511
II. Historical Background	512
III. Basic Principles and Methods of Protein Crystallography	514
IV. Applications	527
V. Two Selected Examples	531
VI. Outlook	532
References	533

23. Physiological Aspects Determining the Pharmacokinetic Properties of Drugs

KOEN BOUSSERY, FRANS M. BELPAIRE AND JOHAN VAN DE VOORDE

I. Introduction	539
II. Passage of Drugs Through Biological Barriers	541
III. Drug Absorption	542
IV. Drug Distribution	547
V. Drug Elimination	548
VI. Some Pharmacokinetic Parameters and Terminology	552
VII. Variability in Pharmacokinetics	557
Further Reading	559

24. Biotransformation Reactions and their Enzymes

BERNARD TESTA AND BERND CLEMENT

I. Introduction	561
II. Functionalization Reactions	563
III. Conjugation Reactions	571
IV. Biological Factors Influencing Drug Metabolism	579
V. What is the Relative Significance of These Many Types of Metabolic Reactions?	580
VI. Concluding Remarks	581
References	582

25. Biotransformations Leading to Toxic Metabolites: Chemical Aspects

ANNE-CHRISTINE MACHEREY AND PATRICK M. DANSETTE

I. Historical Background	585
II. Introduction	586
III. Reactions Involved in Bioactivation Processes	587
IV. Examples of Metabolic Conversions Leading to Toxic Metabolites	599
V. Conclusion	608
Acknowledgments	611
References	611

26. Drug Transport Mechanisms and their Impact on the Disposition and Effects of Drugs

JEAN-MICHEL SCHERRMANN

I. Introduction	615
II. Biology and Function of Transporters	616
III. Transporters in Drug Disposition	620
IV. Roles of Transporters in Drug Pharmacokinetics, Pharmacodynamics and Toxicology	624
V. Conclusion	628
Acknowledgments	628
References	628

27. Strategies for Enhancing Oral Bioavailability and Brain Penetration

GERHARD GROSS

I. Introduction	631
-----------------	-----

II. Enhancing Oral Bioavailability	632
III. Enhancing Brain Penetration	645
References	653

28. Designing Prodrugs and Bioprecursors

YONG MI CHOI-SLEDESKI AND CAMILLE G. WERMUTH

I. Introduction	657
II. The Different Kinds of Prodrugs	658
III. Practical Applications of Carrier Prodrugs	661
IV. Unique Approaches to Carrier Prodrug Design	668
V. Bioprecursor Prodrug Examples	686
VI. Discussion	690
VII. Difficulties and Limitations	690
VIII. Conclusion	691
References	692

VI

CHEMICAL MODIFICATIONS INFLUENCING THE PHARMACOKINETIC PROPERTIES

29. Drug Delivery with Organic Solvents or Colloidal Dispersed Systems

BERND U. RIEBESEHL

I. Introduction	699
II. Physicochemical Drug Properties	700
III. Oral Drug Delivery	700
IV. Parenteral Drug Delivery	704
References	720

30. Preparation of Water-Soluble Compounds by Covalent Attachment of Solubilizing Moieties

CAMILLE G. WERMUTH AND DOMINIQUE LESUISSE

I. Introduction	723
II. Solubilization Strategies	724
III. Acidic Solubilizing Chains	726
IV. Basic Solubilizing Chains	734
V. Nonionizable Side Chains	739
VI. Concluding Remarks	741
References	742

31. Improving the Water-Solubility of Compounds by Molecular Modification to Disrupt Crystal Packing

MINORU ISHIKAWA AND YUICHI HASHIMOTO

I. Introduction	747
II. Rationale for Disruption of Crystal Packing as an Alternative Method to Improve Solubility	748
III. Improvement of Solubility by Disrupting Intermolecular Hydrogen Bonds	749

IV. Improvement of Solubility by Disrupting Molecular Planarity	751
V. Improvement of Solubility by Bending the Molecular Structure	760
VI. Advantages of Improving Solubility by Molecular Modification to Weaken Intermolecular Interaction	762
VII. Conclusion	763
References	764

32. Chemical and Physicochemical Approaches to Solve Formulation Problems

HARVEY LIEBERMAN AND N. MURTI VEMURI

I. Introduction	767
II. Stability	767
III. Bioavailability	774
IV. Modifying the Duration of Action	781
V. Manufacturing Issues	782
VI. Adapting to Patient's Needs	783
References	788

33. Discover a Drug Substance, Formulate, and Develop It to a Product

PIERRE deMONTIGNY, DAVID HARRIS, CHRIS HO, FRANZ WEIBERTH, BRUNO GALLI AND BERNARD FALLER

I. Introduction	793
II. The Discovery Phase	794
III. Defining Experimental Formulations, the Creative Phase	796
IV. Preparation for a New Drug-Product Launch	800
V. Conclusion: Drug Discovery and Development in Industry	801
Reference	802

VII

PHARMACEUTICAL AND CHEMICAL MEANS TO SOLUBILITY AND FORMULATION PROBLEMS

34. Drug Nomenclature

RAFFAELLA G. BALOCCO MATTAVELLI, JI-CUI DONG, SOPHIE LASSEUR, A. ROMEO AND SABINE KOPP

I. Introduction	807
II. Trade Names and Nonproprietary Names	807

III. Drug Nomenclature	808
IV. Use and Protection of Nonproprietary Names	819
V. Summary	819
References	820
Annex	820

35. Web Alert: Using the Internet for Medicinal Chemistry

DAVID CAVALLA

I. Introduction	825
II. Blogs	826
III. Wikis	826
IV. Compound Information	827
V. Biological Properties of Compounds	829
VI. Drug Information	831
VII. Physical Chemical Information	832
VIII. Prediction and Calculation of Molecular Properties	832
IX. Chemical Suppliers	834
X. Chemical Synthesis	835
XI. Chemoinformatics Software Programs	836
XII. Chemical Analysis	836
XIII. Chemical Publications	837
XIV. Patent Information	838
XV. Toxicology	839
XVI. Meta-Sites and Technology Service Provider Databases	841
XVII. Conclusion	842

36. Protection of Inventions in Medicinal Chemistry

RICHARD LUTHI AND CHRISTOPHER BRICE

I. Patents and the Medicinal Chemist	843
II. What Kinds of Medical Inventions can be Patented?	845
III. The Basics of Patent Law	846
IV. The Role of the Medicinal Chemist in the Patent Arena	858
V. Patents as a Source of Scientific Information	860
VI. Other Forms of Protection	861
VII. Conclusion	862

Index

863

List of Contributors

- Anne Badel** UMR-S973, MTi, University Paris Diderot, Paris, France
- Patrick Bazzini** PC SAS, Bd Gonthier d’Andernach, Illkirch, France
- Frans M. Belpaire** Heymans Institute for Pharmacology, Gent, Belgium
- Alexandre Borrel** University of Helsinki, Helsinki, Finland; UMR-S973, MTi, University Paris Diderot, Paris, France
- Koen Boussey** Laboratory of Medical Biochemistry and Clinical Analysis, Faculty of Pharmaceutical Sciences, Gent University, Gent, Belgium
- Christopher Brice** Consultant, Luthi & Co., Intellectual Property Law Offices, of Tel Aviv, Israel
- Anne-Claude Camproux** UMR-S973, MTi, University Paris Diderot, Paris, France
- David Cavalla** Numedicus Ltd, Cambridge, England
- Paola Ciapetti** Head of Medicinal Chemistry, Novalyst Discovery, Illkirch, Cedex, France
- Hongming Chen** Chemistry Innovation Centre, Discovery Sciences, AstraZeneca R&D, Mölndal, Sweden
- Yong Mi Choi-Sledeski** Sanofi, Boston, MA, USA
- Bernd Clement** Pharmaceutical Institute, Christian Albrechts-University, Gutenbergstraße, Kiel, Germany
- Gordon M. Cragg** NIH Special Volunteer, Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, United States National Cancer Institute, Frederick, Maryland, USA
- Patrick M. Dansette** Laboratoire de Chimie et Biochimie Pharmacologique et Toxicologique, Université Paris Descartes, Sorbonne Paris Cité, Paris
- Pierre deMontigny** Sanofi, Waltham, MA, U.S.A
- Ji-Cui Dong** INN Programme, World Health Organization, Geneva Essential Medicines and Health Products, Regulation of Medicines and Other Health, Technologies, Technologies Standards and Norms
- Iain G. Dougall** IGD Consultancy Ltd, Loughborough, Leics, UK
- Ola Engkvist** Chemistry Innovation Centre, Discovery Sciences, AstraZeneca R&D, Mölndal, Sweden
- Bernard Faller** Novartis Pharma AG, Werk Klybeck Klybeckstrasse, Basel, Switzerland
- Bennett T. Farmer** Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA
- Delphine Flatters** UMR-S973, MTi, University Paris Diderot, Paris, France
- Bruno Galli** Novartis Pharma AG, Lichtstrasse, Basel, Switzerland
- Colette Geneix** UMR-S973, MTi, University Paris Diderot, Paris, France
- Bruno Giethlen** Novartis Pharma AG, Basel, Switzerland
- Serge Grisoni** Pierre Fabre Research Institute, Toulouse, Cédex, France
- Gerhard Gross** Scientific Director at Janssen in Beerse, Belgium
- David Harris** Sanofi, Waltham, MA, U.S.A
- Yuichi Hashimoto** Institute of Molecular and Cellular Biosciences, The University of Tokyo, Japan
- Chris Ho** Sanofi, Waltham, MA, U.S.A
- Andrew L. Hopkins** College of Life Sciences, University of Dundee, Dundee, Scotland, UK
- Hiba Abi Hussein** UMR-S973, MTi, University Paris Diderot, Paris, France
- Peter Imming** Institut fuer Pharmazie, Martin-Luther-Universitaet Halle-Wittenberg, Halle, Germany
- Minoru Ishikawa** Institute of Molecular and Cellular Biosciences, The University of Tokyo, Japan
- Tim Jonckers** Janssen Research & Development Janssen Infectious Diseases – Diagnostics BVBA , Turnhoutseweg, Beerse, Belgium
- Sabine Kopp** World Health Organization, Geneva Essential Medicines and Health Products, Regulation of Medicines and Other Health, Technologies, Technologies Standards and Norms
- David G.I. Kingston** Department of Chemistry and the Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, Virginia, USA
- Thierry Kogej** Chemistry Innovation Centre, Discovery Sciences, AstraZeneca R&D, Mölndal, Sweden
- Sophie Lasseur** INN Programme, World Health Organization, Geneva Essential Medicines and Health Products, Regulation of Medicines and Other Health, Technologies, Technologies Standards and Norms
- Dominique Lesuisse** Lead Generation Board, Sanofi, AVENUE PIERRE BROSOLETTTE, CHILLY MAZARIN - France
- Harvey Lieberman** Sanofi ,Waltham, MA, USA
- Richard Luthi** Founding partner, Luthi & Co., Intellectual Property Law Offices, of Tel Aviv, Israel
- Anne-Christine Macherey** Prévention du Risque Chimique, Gif sur Yvette, France

- André Mann** LAAS-CNRS, Université Louis Pasteur, Strasbourg, France
- Raffaella G. Balocco Mattavelli** INN Programme, World Health Organization, Geneva Essential Medicines and Health Products, Regulation of Medicines and Other Health, Technologies, Technologies Standards and Norms
- Christophe Morice** Prestwick Chemical Inc., Boulevard Gonthier, Illkirch, France
- Richard Morphy** Eli Lilly, Erl Wood Manor, Windlesham, Surrey, UK
- David J. Newman** NIH Special Volunteer, Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, United States National Cancer Institute, Frederick, Maryland, USA
- Anne Olivier** Sanofi-Aventis Recherche et Développement, Chilly-Mazarin, France
- Michel Petitjean** UMR-S973, MTi, University Paris Diderot, Paris, France
- Pierre Raboisson** Janssen Infectious Diseases and Diagnostics BVBA, Beerse, Belgium
- Zoran Rankovic** Eli Lilly, Indianapolis, IN, USA
- Leslie Regad** UMR-S973, MTi, University Paris Diderot, Paris, France
- Allen B. Reitz** Fox Chase Chemical Diversity Center, Inc., Doylestown, PA, USA
- Bernd U. Riebesehl** Technical Research & Development, Novartis Pharma AG, Basel, Switzerland
- Jean-Philippe Rocher** Pierre Fabre Research Institute, Castres, France
- Tiago Rodrigues** Swiss Federal Institute of Technology (ETH), Department of Chemistry and Applied Biosciences, Zürich, Switzerland
- A. Romeo** INN Programme, World Health Organization, Geneva Essential Medicines and Health Products, Regulation of Medicines and Other Health, Technologies, Technologies Standards and Norms
- Jean-Michel Rondeau** Novartis Institutes for BioMedical Research, Basel, Switzerland
- Laurent Schaeffer** Prestwick Chemical Inc., Boulevard Gonthier, Illkirch, France
- Jean-Michel Scherrmann** Department of Pharmaceutical Sciences, University Paris Descartes, Paris, France
- Gisbert Schneider** Swiss Federal Institute of Technology (ETH), Department of Chemistry and Applied Biosciences, Zürich, Switzerland
- Herman Schreuder** Sanofi, R&D LGCR/Struct., Design & Informatics FF, Frankfurt am Main, Germany
- Wolfgang Sippl** Medicinal Chemistry, Institute of Pharmacy, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Germany
- Erin M. Skoda** Department of Chemistry, University of Pittsburgh, Pittsburgh, PA, USA
- Olivier Taboureau** UMR-S973, MTi, University Paris Diderot, Paris, France
- Bernard Testa** Department of Pharmacy, Lausanne University Hospital (CHUV), Lausanne, Switzerland
- John Unitt** Syngene Discovery Limited, BioCity, Nottingham, UK
- Johan Van de Voorde** Vascular Research Unit, Ghent University, Ghent, Belgium
- Walter M.M. Van den Broeck** Janssen Infectious Diseases BVBA, Beerse, Belgium
- N. Murti Vemuri** CMC Subject Matter Expert at BARDA/HHS, Conceptual MindWorks, Inc., Flemington, NJ, USA
- Venkata Velvadapu** Fox Chase Chemical Diversity Center, Inc., Doylestown, PA, USA
- Franz Weiberth** Sanofi, Waltham, MA, U.S.A
- Bruno Villoutreix** Université Paris Diderot, Sorbonne Paris Cité, Inserm, Paris, France
- Camille G. Wermuth** Founder of Prestwick Chemical, Strasbourg, France
- Peter Wipf** Department of Chemistry, University of Pittsburgh, Pittsburgh, PA, USA
- Gerhard Wolber** Computer-Aided Molecular Design, Institute of Pharmacy, Freie Universität Berlin, Königin-Luisestr., Berlin, Germany

Foreword

The world's economy depends to a significant extent on our ability to deliver affordable and sustainable healthcare. As such, this new edition of *The Practice of Medicinal Chemistry* plays an important role in educating the next generation of scientists in the area as it goes beyond the simple delivery of new healing drugs to combat disease and illness. It enriches our knowledge and the very understanding of the lives of everyone on the planet. It is truly amazing how the different scientific disciplines can combine in this way to design and make such a wonderful array of functional molecules to serve some of our current needs. Nevertheless, the future presents enormous healthcare challenges that can only be met by appropriate investment and further fundamental scientific discovery. This new edition of *The Practice of Medicinal Chemistry* provides a unique scholarly compilation of the tools, techniques, and methods necessary to begin this journey of discovery, whether in industry or academia.

The book's practical overview differentiates this text from others. It provides a menu of topics that can be consulted individually, while also providing a holistic view covering the history of drug discovery through to the issues of today involving the consumption and production of pharmaceuticals. The process of drug discovery has become a highly complex operation requiring the medicinal chemist to acquire wide-ranging skills from areas such as biology, technology, modelling, delivery, physiochemistry, and synthesis. To pull this together in a single book is a heroic task that these authors have done magnificently.

As our science moves forward toward more biologicals, smaller volume products that are focused on patients, and more sustainable and flexible manufacturing in an ever more regulated environment, we will require new generations of creative individuals. They will need to be ever more innovative, using all the tools our modern society can offer. In particular, big-data mining, tissue sampling and genomic mapping, the "Internet of Things," and wearable health monitors will all be likely components in the armory of the next breed of medicinal chemist.

I regard this expanded textbook as essential reading for all those new to the field. It also provides a quality check for current practitioners in this rapidly evolving environment. The book also does not shy away from providing a future vision of the trends of the discipline. It is written by experts who elegantly convey their passion, experience, and insight for the benefit of all readers.

I therefore welcome this updated and expanded version of *The Practice of Medicinal Chemistry* and believe it provides—as did past editions—the bedrock of our discipline.

Steven V. Ley
Cambridge

<http://www.leygroup.ch.cam.ac.uk/>

Preface to the Fourth Edition

Bringing a new drug to patients is both a privilege and a challenge fraught with success and failure. A privilege because there can be no greater calling than to alleviate suffering to enable a healthier life.

Without health, life is not life; it is only a state of languor and suffering—an image of death. *Buddha*

A challenge fraught with success and failure as no drug makes it from idea to patients without experiencing success and failure.

Success is not final; failure is not fatal. It is the courage to continue that counts. *Winston Churchill*

Prof. Camille Wermuth recognized the need to capture in a single volume the essence of the disciplines needed by medicinal chemists, so as to enable those just entering the field or the seasoned professional to keep pace with the ever-changing nature of drug discovery and development. His vision became *The Practice of Medicinal Chemistry*, providing the medicinal chemistry community with access to experts from across the industry and academia who would share their knowledge to educate the community, thereby preparing the community to recognize and seize opportunities as they emerged.

Fortune favors the prepared mind. *Louis Pasteur*

The fourth edition has built off the previous editions. It is updated to reflect developments over the last seven years, including five new chapters on topics such as the evaluation of the biological activity of compounds and systems biology. More than seventy experts from ten countries have shared their insights and perspectives on the practice of medicinal chemistry.

The editorial work for the fourth edition has been shared by Camille Wermuth, Pierre Raboisson, Didier Rognan, and Dave Aldous. Odile Blin helped organize and shape how we initiated the fourth edition; we are indebted to her tireless professionalism. The editors wish to express their thanks to Molly M. McLaughlin and the Elsevier Academic Press, who have worked with us to keep this project moving forward.

I believe my final quote—from Jason Calacanis—captures the challenges medicinal chemists face every day.

You have to have a big vision and take very small steps to get there. You have to be humble as you execute but visionary and gigantic in terms of your aspiration. In the Internet industry, it's not about grand innovation; it's about a lot of little innovations—every day, every week, every month—making something a little bit better. *Jason Calacanis*

Medicinal chemistry is a highly collaborative and iterative process that has many paths. Being open, collaborative, and humble are qualities that will help you successfully navigate these paths from idea to patient.

Preface to the Third Edition

Like the preceding editions of this book, this third edition treats of the essential elements of medicinal chemistry in a unique volume. It provides a practical overview of the daily problems facing medicinal chemists, from the conception of new molecules through to the production of new drugs and their legal/economic implications. This edition has been updated, expanded and refocused to reflect developments in the past 5 years, including 11 new chapters on topics such as hit identification methodologies and cheminformatics. More than 50 experts in the field from eight different countries, who have benefited from years of practical experience, give personal accounts of both traditional methodologies and the newest discovery and development technologies, providing readers with an insight into medicinal chemistry.

A major change in comparison to the previous editions was the decision to alleviate my editorial burden in sharing it with seven section editors, each being responsible for one of the eight sections of the book. I highly appreciated their positive and efficacious collaboration and express them my warmest thanks (in the alphabetical order) to Michael Bowker, Hugo Kubinyi, John Proudfoot, Bryan Reuben, Richard Silverman, David Triggler and Han van de Waterbeemd.

Another change was the decision taken by Elsevier/Academic Press to publish the book in full colors thus rendering it more pleasant and user-friendly. I take this occasion to thank Keri Witman, Pat Gonzales, Kirsten Funk and Renske van Dijk for having successively ensured the editorial development of the book. Taking into account that we had to work with a cohort of about 50 authors, each of them having his personality, his original approach and his main busy professional live, this was not an easy task. I am deeply indebted to my assistant Odile Blin for the way she had mastered, efficiently and with friendliness, all the secretarial work and particularly the contacts with the different authors and with the Elsevier development editors. As for the earlier editions, I also want to express my gratitude to my wife Renée and my daughters Delphine, Joëlle and Séverine for all their encouragements and for sacrificing many hours of family life in order to leave me enough free time to edit this new version of the "Medicinal Chemist's Bible."

My final thoughts go to the future readers of the book, and especially to the newcomers in Medicinal Chemistry having the curiosity to read the preface. I cannot resist giving them some advice for doing good science.

First of all, be open-minded and original. As Schopenhauer noted, the task of the creative mind is "not so much to see what no one has seen yet; but to think what nobody has thought yet, about what everyone sees." A wonderful illustration is found in Peter Hesse's cartoon below.

Second, always keep in mind that the object of Medicinal Chemistry is to synthesize new drugs useful for suffering patients. Like many scientists, medicinal chemists, have to navigate between two tempting reefs. On one side they should avoid doing "NAAR": non-applicable applied research, on the other side they may be attracted by "NFBR": non-fundamental basic search."

Third, convinced as they may be that the neighbors grass is always greener, they may be attracted to start their research in using as a hit a recently published competitor's product. In fact, the published compound may exhibit only a weak activity, therefore be very careful when starting a new program and never forget that the worst thing a medicinal chemist can do is to prepare a me-too of an inactive compound!

Camille G. Wermuth

Preface to the Second Edition

Like the first edition of *The Practice of Medicinal Chemistry* (nicknamed ‘The Bible’ by medicinal chemists) the second edition is intended primarily for organic chemists beginning a career in drug research. Furthermore, it is a valuable reference source for academic, as well as industrial, medicinal chemists. The general philosophy of the book is to complete the biological progress – Intellectualization at the level of function using the chemical progress Intellectualization at the level of structure (Professor Samuel J. Danishevsky, *Studies in the chemistry and biology of the epothilones and eleutherobins*, Conference given at the XXXIV^{èmes} Rencontres Internationales de Chimie Thérapeutique, Faculté de Pharmacie, Nantes, 8–10 July, 1998).

The recent results from genomic research have allowed for the identification of a great number of new targets, corresponding to hitherto unknown receptors or to new subtypes of already existing receptors. The massive use of combinatorial chemistry, associated with high throughput screening technologies, has identified thousands of hits for these targets. The present challenge is to develop these hits into usable and useful drug candidates. This book is, therefore, particularly timely as it covers abundantly the subject of drug optimization.

The new edition of the book has been updated, expanded and refocused to reflect developments over the nine years since the first edition was published. Experts in the field have provided personal accounts of both traditional methodologies, and the newest discovery and development technologies, giving us an insight into diverse aspects of medicinal chemistry, usually only gained from years of practical experience.

Like the previous edition, this edition includes a concise introduction covering the definition and history of medicinal chemistry, the measurement of biological activities and the three main phases of drug activity. This is followed by detailed discussions on the discovery of new lead compounds including automated, high throughput screening techniques, combinatorial chemistry and the use of the internet, all of which serve to reduce pre-clinical development times and, thus, the cost of drugs. Further chapters discuss the optimization of lead compounds in terms of potency, selectivity, and safety; the contribution of genomics; molecular biology and X-ray crystallization to drug discovery and development, including the design of peptidomimetic drugs; and the development of drug-delivery systems, including organ targeting and the preparation of pharmaceutically acceptable salts. The final section covers legal and economic aspects of drug discovery and production, including drug sources, good manufacturing practices, drug nomenclature, patent protection, social-economic implications and the future of the pharmaceutical industry.

I am deeply indebted to all co-authors for their cooperation, for the time they spent writing their respective contributions and for their patience during the editing process. I am very grateful to Didier Rognan, Paola Ciapetti, Bruno Giethlen, Annie Marcincal, Marie-Louise Jung, Jean-Marie Contreras and Patrick Bazzini for their helpful comments.

My thanks go also to the editorial staff of *Academic Press* in London, particularly to Margaret Macdonald and Jacqueline Read. Last but not least, I want to express my gratitude to my wife Renée for all her encouragements and for her comprehensiveness.

Camille G. Wermuth

Preface to the First Edition

The role of chemistry in the manufacture of new drugs, and also of cosmetics and agrochemicals, is essential. It is doubtful, however, whether chemists have been properly trained to design and synthesize new drugs or other bioactive compounds. The majority of medicinal chemists working in the pharmaceutical industry are organic synthetic chemists with little or no background in medicinal chemistry who have to acquire the specific aspects of medicinal chemistry during their early years in the pharmaceutical industry. This book is precisely aimed to be their 'bedside book' at the beginning of their career.

After a concise introduction covering background subject matter, such as the definition and history of medicinal chemistry, the measurement of biological activities and the three main phases of drug activity, the second part of the book discusses the most appropriate approach to *finding a new lead compound or an original working hypothesis*. This most uncertain stage in the development of a new drug is nowadays characterized by high-throughput screening methods, synthesis of combinatorial libraries, data base mining and a return to natural product screening. The core of the book (Parts III to V) considers the *optimization of the lead in terms of potency, selectivity, and safety*. In 'Primary Exploration of Structure-Activity Relationships', the most common operational stratagems are discussed, allowing identification of the portions of the molecule that are important for potency. 'Substituents and functions' deals with the rapid and systematic optimization of the lead compound. 'Spatial Organization, Receptor Mapping and Molecular Modelling' considers the three-dimensional aspects of drug-receptor interactions, giving particular emphasis to the design of peptidomimetic drugs and to the control of the agonist-antagonist transition. Parts VI and VII concentrate on the definition of satisfactory drug-delivery conditions, i.e. means to ensure that the molecule reaches its target organ. Pharmacokinetic properties are improved through adequate chemical modifications, notably prodrug design, obtaining suitable water solubility (of utmost importance in medical practice) and improving organoleptic properties (and thus rendering the drug administration acceptable to the patient). Part VIII, 'Development of New Drugs: Legal and Economic Aspects', constitutes an important area in which chemists are almost wholly self taught following their entry into industry.

This book fills a gap in the available bibliography of medicinal chemistry texts. There is not, to the author-editor's knowledge, any other current work in print which deals with the practical aspects of medicinal chemistry, from conception of molecules to their marketing. In this single volume, all the disparate bits of information which medicinal chemists gather over a career, and generally share by word-of-mouth with their colleagues, but which have never been organized and presented in coherent form in print, are brought together. Traditional approaches are not neglected and are illustrated by modern examples and, conversely, the most recent discovery and development technologies are presented and discussed by specialists. Therefore, *The Practice of Medicinal Chemistry* is exactly the type of book to be recommended as a text or as first reading to a synthetic chemist beginning a career in medicinal chemistry. And, even if primarily aimed at organic chemists entering into pharmaceutical research, all medicinal chemists will derive a great deal from reading the book.

The involvement of a large number of authors presents the risk of a certain lack of cohesiveness and of some overlaps, especially as each chapter is written as an autonomic piece of information. Such a situation was anticipated and accepted, especially for a first edition. It can be defended because each contributor is an expert in his/her field and many of them are 'heavyweights' in medicinal chemistry. In editing the book I have tried to ensure a balanced content and a more-or-less consistent style. However, the temptation to influence the personal views of the authors has been resisted. On the contrary, my objective was to combine a plurality of opinions, and to present and discuss a given topic from different angles. Such as it is, this first edition can still be improved and I am grateful in advance to all colleagues for comments and suggestions for future editions.

Special care has been taken to give complete references and, in general, each compound described has been identified by at least one reference. *For compounds for which no specific literature indication is given, the reader is referred to the Merck Index.*

The cover picture of the book is a reproduction of a copperplate engraving designed for me by the late Charles Gutknecht, who was my secondary school chemistry teacher in Mulhouse. It represents an extract of Brueghel's engraving *The alchemist ruining his family in pursuing his chimera*, surmounted by the aquarius symbol. Represented on the left-hand side is my lucky charm castor oil plant (*Ricinus communis* L., *Euphorbiaceae*), which was the starting point of the pyridazine chemistry in my laboratory. The historical cascade of events was as follows: cracking of castor oil produces n-heptanal and aldolization of n-heptanal – and, more generally, of any enolisable aldehyde or ketone – with pyruvic acid leads to α -hydroxy- γ -ketonic acids. Finally, the condensation of these keto acids with hydrazine yields pyrodazones. Thus, all our present research on pyridazine derivatives originates from my schoolboy chemistry, when I prepared in my home in Mulhouse n-heptanal and undecylenic acid by cracking castor oil!

Preparing this book was a collective adventure and I am most grateful to all authors for their cooperation and for the time and the effort they spent to write their respective contributions. I appreciate also their patience, especially as the editing process took much more time than initially expected.

I am very grateful to Brad Anderson (University of Utah, Salt Lake city), Jean-Jacques André (Marion Merrell Dow, Strasbourg), Richard Baker (Eli Lilly, Erl Wood, UK), Thomas C. Jones (Sandoz, Basle), Isabelle Morin (Servier, Paris), Bryan Reuben (London South Bank University) and John Topliss (University of Michigan, Ann Arbor) for their invaluable assistance, comments and contributions.

My thanks go also to the editorial staff of Academic Press in London, Particularly to Susan Lord, Nicola Linton and Fran Kingston, to the two copy editors Len Cegiela and Peter Cross, and finally, to the two secretaries of our laboratory, François Herth and Marylse Wernert.

Last but not least, I want to thank my wife Renée for all her encouragement and for sacrificing evenings and Saturday family life over the past year and a half, to allow me to sit before my computer for about 2500 hours!

Camille G. Wermuth

SECTION ONE

General Aspects of Medicinal Chemistry

1

Medicinal Chemistry: Definitions and Objectives, Drug Activity Phases, Drug Classification Systems

Peter Imming

Institut fuer Pharmazie, Martin-Luther-Universitaet Halle-Wittenberg, Halle, Germany

OUTLINE

I. Definitions and Objectives	3	C. <i>The Pharmacodynamic Phase</i>	8
A. <i>Medicinal Chemistry and Related Disciplines and Terms</i>	3	D. <i>The Road to Successful Drug Development?</i>	8
B. <i>Drugs and Drug Substances</i>	4	III. Drug Classification Systems	8
C. <i>Stages of Drug Development</i>	5	A. <i>Classification by Target and Mechanism of Action</i>	8
II. Drug Activity Phases	7	B. <i>Other Classification Systems</i>	11
A. <i>The Pharmaceutical Phase</i>	7	References	12
B. <i>The Pharmacokinetic Phase</i>	7		

Medicinal chemistry remains a challenging science which provides profound satisfaction to its practitioners. It intrigues those of us who like to solve problems posed by nature. It verges increasingly on biochemistry and on all the physical, genetic and chemical riddles in animal physiology which bear on medicine. Medicinal chemists have a chance to participate in the fundamentals of prevention, therapy and understanding of diseases and thereby to contribute to a healthier and happier life. **A Burger [1]**

I. DEFINITIONS AND OBJECTIVES

A. Medicinal Chemistry and Related Disciplines and Terms

A definition of medicinal chemistry was given by a IUPAC specialized commission: “*Medicinal chemistry* concerns the discovery, the development, the identification and the interpretation of the mode of action of biologically active compounds at the molecular level. Emphasis is put on drugs, but the interests of the medicinal chemist are not restricted to drugs but include bioactive compounds in general. Medicinal chemistry is also concerned with the study, identification, and synthesis of the metabolic products of these drugs and related compounds” [2].

Drugs—natural and synthetic alike—are chemicals used for medicinal purposes. They interact with complex chemical systems of humans or animals. Medicinal chemistry is concerned with this interaction, focusing on the organic and biochemical reactions of drug substances with their targets. This is one aspect of drug chemistry.

Other important aspects are the synthesis and the analysis of drug substances. The two latter aspects together are sometimes called *pharmaceutical chemistry*, but the synthesis of drugs is considered by some people—mainly chemists—to be part of medicinal chemistry, denoting analytical aspects as pharmaceutical chemistry. In German faculties of pharmacy, the literal translations of pharmaceutical and medicinal chemistry—Pharmazeutische and Medizinische Chemie—are used synonymously.

The general study of drugs is called *pharmacy* or *pharmacology*. A common narrower definition of pharmacology concentrates on the fate and effects of a drug in the body. *Clinical chemistry*, a different subject, is concerned with the determination of physiological and pathophysiological parameters in body fluids, such as enzyme activities and metabolites in blood and urine. The term *biopharmacy* has been reserved for the investigation and control of absorption, distribution, metabolism, excretion, and toxicology (ADMET) of drug substances.

Some further terms are more or less synonymous with medicinal chemistry: (*molecular*) *pharmacochemistry*, *drug design*, *selective toxicity*. The French equivalent to medicinal chemistry is *chimie thérapeutique*, and the German terms are Medizinische/Pharmazeutische Chemie and Arzneimittelforschung.

In academia, medicinal chemistry is a major subject in most pharmacy faculties—both for undergraduates and in research—and in many chemistry faculties. In the pharmaceutical industry, medicinal chemistry is at the heart of the search for new medicines.

The main activities of medicinal chemists are evident in the analysis of their most important scientific journals (e.g., *Journal of Medicinal Chemistry*, *European Journal of Medicinal Chemistry*, *Bioorganic and Medicinal Chemistry*, *ChemMedChem*, *Archiv der Pharmazie*, *Arzneimittelforschung*, *Chemical and Pharmaceutical Bulletin*).

The *objectives of medicinal chemistry* are as easily formulated as they are difficult to achieve: find, develop, and improve drug substances that cure or alleviate diseases (see below, [Section I.C.](#)) and understand the causative and accompanying chemical processes (see below, [Section III.A](#)).

Medicinal chemistry is an interdisciplinary science covering a particularly wide domain situated at the interface of organic chemistry with life sciences such as biochemistry, pharmacology, molecular biology, genetics, immunology, pharmacokinetics, and toxicology on one side, and chemistry-based disciplines such as physical chemistry, crystallography, spectroscopy, and computer-based techniques of simulation, data analysis, and data visualization on the other side.

B. Drugs and Drug Substances

Drugs are composed of *drug substances* (syn. *active pharmaceutical ingredients*, *APIs*) and *excipients* (syn. *ancillary substances*). The combination of both is the work of pharmaceutical technology (syn. *galenics*) and denoted a *formulation*.

In 2014, the World Drug Index contained over 80,000 marketed and development drug substances [3]. The United States *Orange Book* listed approx. 3,500 products in 2014, and the United States Pharmacopeia contains monographs of approx. 1,400 small-molecules Active Pharmaceutical Ingredients (APIs) and 160 biologic drug substances [4]. In 2013 in Germany, the “Rote Liste” contained approximately 6,000 drugs in 7,500 formulations representing approximately 2,000 APIs [5]. The WHO Essential Medicines List held approximately 350 drug substances in 2013 that WHO claims sufficient for the treatment of approx. 90 percent of all diseases where drugs are useful [6].

What makes a chemical “drug-like?” Because of the versatility of their molecular targets (see below), there can be no universal characteristic of drug substances. However, since the general structure of the target organisms is identical, generalizations as to drug substance structure are possible for biopharmacy [7,8]. For a chemical to be readily absorbed by the gut and distributed in the body, its size, hydrophilicity/lipophilicity ratio, stability toward acid media and hydrolytical enzymes, etc. have to meet defined physicochemical criteria. A careful analysis of reasons for drug attrition revealed that only 5 percent were caused by pharmacokinetic difficulties, whereas 46 percent were due to insufficient efficacy and 33 percent to adverse reactions in animals or humans [9]. Since both wanted and unwanted effects are due to the biological activity, 79 percent of drug candidates had unpredicted or wrongly predicted sum activities.

Predictions of toxicity from molecular features are still precarious [10–12]. Only rather general rules are for sure; such as avoidance of very reactive functional groups, for example, aldehyde because of oxidative instability and haptene nature; α,β -unsaturated carbonyl compounds and 2-halopyridines because of their unspecific reactivity as electrophiles. Torcetrapib is a typical example of toxicity—or adverse effects—challenges. It was an anti-atherosclerotic drug candidate promising to become a blockbuster when in latter phase III of clinical trials, an increased risk of mortality led the company to discontinue its development. It was not clear whether the effects

were caused by the mechanism of action—inhibition of cholesteryl ester transfer protein—some other effect or an interaction with another drug. This is just one instance that “it isn’t that simple [and] nothing’s obvious and nothing’s for certain” in rational drug development [13].

C. Stages of Drug Development

Most drugs were discovered rather than developed [14]. That is why a large number of drug substances are natural products or derivatives thereof. It is a matter of debate if ethnic medicines or nature still hold gems as yet undiscovered by pharmacy [15,16]. Synthetic substance collections (“libraries”) have been created through (automated) organic chemistry. The very high number and diversity of natural and synthetic chemical entities is faced with an equally growing number of potential reaction partners (targets) from biochemical and pathophysiological research.

In virtual, biochemical and cell-based testing, compound selections are run against an isolated or physiologically embedded target that may be involved in the disease process [17]. Compounds that exceed a certain threshold value in binding to the target or modulation of some functional signal behind it, are called *hits*. If the identity and purity of the compound and the assay result are confirmed in a multipoint activity determination, the compound rises to the status of *validated hit*. From this one hopes to develop leads. A *lead* is a compound or series of compounds with proven activity and selectivity in a screen and fulfills some drug development criteria such as originality, patentability, and accessibility (by extraction or synthesis). Molecular variation hopefully tunes the physicochemical parameters so that it becomes suitable for ADME. An example of a small optimization algorithm is shown in Figure 1.1.

If the resulting *optimized lead (preclinical candidate)* displays no toxicity in cell and animal models, it becomes a *clinical candidate*. If this stands the tests of efficacy and safety in humans and overcomes marketing hurdles, a *new drug entity* will enter the treasure trove of pharmacy. Box 1.1 illustrates that activity is a necessary but not sufficient quality of medicines. There is, of course, no ideal drug in the real world, but one has to find a relative optimum. This often means developing a drug that has a different side-effect profile than drugs marketed for the same therapeutic indication so prescriptions can be tailored to the ways different patients react to a drug.

The role of medicinal chemistry is most prominent in steps one and two of drug development:

1. The discovery step, consisting of the choice of the therapeutic target (biochemical, cellular, or *in vivo* model; see below) and the identification or discovery and production of new active substances interacting with the selected target.
2. The optimization step that deals with the improvement of an active compound. The optimization process primarily takes into account the increase in potency, selectivity, and decrease in toxicity. Its characteristics are the establishment of structure–activity relationships, ideally based on an understanding of the molecular mode of action.




FIGURE 1.1 Example of an optimization algorithm. Source: Adapted from a presentation by Dr. U. Heiser, Probiodrug AG, Halle, Germany, reproduced with permission.

3. The formulation step, whose purpose is the continuation of the improvement of the pharmacokinetic properties and the fine-tuning of the pharmaceutical properties of active substances to render them suitable for clinical use. This can consist—to name just a few instances—of the preparation of better absorbed compounds, of sustained release formulations, and of water-soluble derivatives or in the elimination of properties related to the patient's compliance (irritation, painful injection, undesirable organoleptic properties). For an example, see [Figure 1.2](#).

The main tasks of medicinal chemistry consist of the optimization of the following characteristics:

- Higher affinity and target-intrinsic activation for better clinical activity so the dosage and nonspecific side effects will be as low as possible. There are no examples of drugs that are dosed below 10 mg/day that cause idiosyncratic adverse drug reactions. For drug substances that have to be given in higher doses—i.e., the majority—medicinal chemistry tries to find active derivatives that will be metabolized in a safe way [18]. This includes assaying for inhibition of or reaction with key enzymes of biotransformation, such as oxidases of the cytochrome type, some of which are highly demanded by food constituents and xenobiotics including drug substances [19]. Medicinal chemistry tries to prepare drugs that are not metabolized by bottleneck enzymic pathways [20].
- Better selectivity, which may lead to a reduction of unwanted side effects. This sometimes entails the assaying of a very high number of other targets; for example, an antidepressive serotonin re-uptake inhibitor has to be tested against all subtypes of serotonin, adrenaline, and dopamine receptors, plus many other key receptors and enzymes.

BOX 1.1

THE IDEAL NEW DRUG SUBSTANCE

- New chemical entity for patentability and registration.
- Maximum four-step synthesis with, for example, no heavy metal catalysts and no environmentally problematic waste; no chromatographic purification steps; purity >99 percent.
- Stable up to 70°C even in humid air and light.
- Solid-state properties (crystalline, not polymorphous, not hygroscopic) that make it a perfect partner for (tablet) compaction.
- Solubility in water sufficient for the production of stable blood-isotonic solutions.
- Oral bioavailability .90 percent with no interindividual variation.
- Very high activity and pharmacokinetic profile enable once-a-day-dosage at 5–10 mg.




FIGURE 1.2 An example of fine-tuning of pharmacologically active chemicals: Erythromycin 29-ethylsuccinate and clarithromycin are semisynthetic derivatives of the macrolide anti-infective erythromycin. The small molecular change in the former leads to the elimination of bitterness which is important as this class of drugs is often used in pediatrics and administered as a syrup. In the latter, because hemiketal formation is no longer possible (arrow), clarithromycin is stable in the acidic milieu of the stomach (pH 2).